Clinical Frailty Score (CFS) versus Hospital Frailty Risk Score (HFRS) for predicting mortality and other adverse outcome in hospitalized patients with COVID-19: Spanish case series

• Published in: International Journal of Clinical Practice 2021
• Main Authors: Ramos-Rincon, Jose-Manuel, Moreno-Perez, Oscar, Pinargote-Celorio, Hector, Leon-Ramirez, Jose-Manuel, Andres, Mariano, Reus, Sergio, Herrera-García, Cristian, Martí-Pastor, Ana, Boix, Vicente, Gil, Joan, Sanchez-Martinez, Rosario, Merino, Esperanza
• Format: Web Resource
• Language: English
• DOI: 10.1111/ijcp.14599

Objectives Frailty can be used as a predictor of adverse outcomes in people with COVID-19. The aim of the study was to analyze the prognostic value of two different frailty scores in patients hospitalized for COVID-19. Material and Methods This retrospective cohort study included adult (≥ 18 years) inpatients with COVID-19 and took place from 3 March to 2 May 2020. Patients were categorized by Clinical Frailty Score (CFS) and Hospital Frailty Risk Score (HFRS). The primary outcome was in-hospital mortality, and secondary outcomes were tocilizumab treatment, length of hospital stay, admission in intensive care unit (ICU), and need for invasive mechanical ventilation. Results were analyzed by multivariable logistic regression and expressed as odds ratios (ORs), adjusting for age, sex, kidney function, and comorbidity. Results Of the 290 included patients, 54 were frail according to the CFS (≥5 points; prevalence 18.6%, 95% confidence interval [CI]: 14.4-23.7) versus 65 by HFRS (≥5 points; prevalence: 22.4%, 95% CI 17.8-27.7). Prevalence of frailty increased with age according to both measures: 50-64 years, CFS 1.9% versus HFRS 12.3%; 65-79 years, CFS 31.5% versus HFRS 40.0%; and ≥ 80 years, CFS 66.7% versus HFRS 40.0% (p